Calgary, Alberta — September 16, 2025 — Leads & Copy — Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) will present data on its VesCell™ (ACP-01) treatment for severe angina pectoris at its weekly webinar on Thursday, September 18, 2025.
Croom Lawrence will present the data, entitled “Treatment of Patients with Severe Angina Pectoris Using Intracoronarily Injected Autologous Blood-Borne Angiogenic Cell Precursors.” The presentation will compare the current standard of care to results from a clinical pilot study of VesCell™ (ACP-01) that were published in Circulation, Volume 114, Number Suppl_18.
The clinical trial evaluated the safety and efficacy of intracoronary injection of autologous Angiogenic Cell Precursors (ACPs) in patients with chronic stable angina who had exhausted maximal drug therapy. The key findings included improved exercise tolerance, enhanced exercise capacity, reduction in ischemia, and symptom relief.
According to Thomas Smeenk, CEO, the study results are a significant step forward. Smeenk stated that ACP-01 therapy uses angiogenic stem cells from the patient’s own blood to improve blood circulation and reduce the disease’s impact. The company will use revenue and data generated from real-world patient experiences to fund a double-blind randomized clinical trial for global approval.
Presentation Details:
Presenter: Croom Lawrence
Title: Treatment of Patients with Severe Angina Pectoris Using Intracoronarily Injected Autologous Blood-Borne Angiogenic Cell Precursors
Date: Thursday, September 18, 2025
Conference Link: Click here to register.
Thomas Smeenk, President, CEO & Co-Founder: EM: tsmeenk@hemostemix.com / PH: 905-580-4170
Source: Hemostemix Inc.
